share_log

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5:募資說明書
美股SEC公告 ·  05/02 08:18

Moomoo AI 已提取核心訊息

Allarity Therapeutics Inc. has filed a prospectus supplement on May 2, 2024, to increase the maximum aggregate offering price of its common stock from $4,500,000 to $7,250,000. This amendment is in accordance with the At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The company has already sold $4,265,000 of its common stock within the last 12 months and is now eligible to sell an additional $2,991,735. The prospectus supplement is part of a registration statement filed on November 29, 2023, and is qualified by the prior prospectus dated March 19, 2024. The company's public float was valued at approximately $21,770,204, with a share price of $8.44 as of March 6, 2024. Allarity Therapeutics cautions that investing in its common stock involves a high degree of risk, as detailed in the 'Risk Factors' section of the prospectus supplement.
Allarity Therapeutics Inc. has filed a prospectus supplement on May 2, 2024, to increase the maximum aggregate offering price of its common stock from $4,500,000 to $7,250,000. This amendment is in accordance with the At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The company has already sold $4,265,000 of its common stock within the last 12 months and is now eligible to sell an additional $2,991,735. The prospectus supplement is part of a registration statement filed on November 29, 2023, and is qualified by the prior prospectus dated March 19, 2024. The company's public float was valued at approximately $21,770,204, with a share price of $8.44 as of March 6, 2024. Allarity Therapeutics cautions that investing in its common stock involves a high degree of risk, as detailed in the 'Risk Factors' section of the prospectus supplement.
Allarity Therapeutics Inc.已於2024年5月2日提交了招股說明書補充文件,將其普通股的最高總髮行價從450萬美元提高到725萬美元。該修正案符合與Ascendiant Capital Markets, LLC簽訂的市場發行銷售協議。在過去的12個月中,該公司已經出售了426.5萬美元的普通股,現在有資格再出售2,991,735美元。招股說明書補充文件是2023年11月29日提交的註冊聲明的一部分,並受2024年3月19日的先前招股說明書的限制。截至2024年3月6日,該公司的公衆持股量約爲21,770,204美元,股價爲8.44美元。Allarity Therapeutics警告說,投資其普通股涉及高度的風險,正如招股說明書補充文件的 “風險因素” 部分所詳述的那樣。
Allarity Therapeutics Inc.已於2024年5月2日提交了招股說明書補充文件,將其普通股的最高總髮行價從450萬美元提高到725萬美元。該修正案符合與Ascendiant Capital Markets, LLC簽訂的市場發行銷售協議。在過去的12個月中,該公司已經出售了426.5萬美元的普通股,現在有資格再出售2,991,735美元。招股說明書補充文件是2023年11月29日提交的註冊聲明的一部分,並受2024年3月19日的先前招股說明書的限制。截至2024年3月6日,該公司的公衆持股量約爲21,770,204美元,股價爲8.44美元。Allarity Therapeutics警告說,投資其普通股涉及高度的風險,正如招股說明書補充文件的 “風險因素” 部分所詳述的那樣。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息